Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential by Kindler, E. (Eveline) et al.
Efficient Replication of the Novel Human Betacoronavirus EMC on
Primary Human Epithelium Highlights Its Zoonotic Potential
Eveline Kindler,a Hulda R. Jónsdóttir,a Doreen Muth,b Ole J. Hamming,c Rune Hartmann,c Regulo Rodriguez,d Robert Geffers,e
Ron A. M. Fouchier,f Christian Drosten,b Marcel A. Müller,b Ronald Dijkman,a Volker Thiela,g
Institute of Immunobiology, Kantonal Hospital, St. Gallen, Switzerlanda; Institute of Virology, University of Bonn Medical Center, Bonn, Germanyb; Department of Molecular
Biology and Genetics, Centre for Structural Biology, University of Aarhus, Aarhus, Denmarkc; Institute of Pathology, Kantonal Hospital, St. Gallen, Switzerlandd; Genome
Analytics Group, Helmholtz Center for Infection Research, Braunschweig, Germanye; Viroscience Lab, Erasmus Medical Center, Rotterdam, The Netherlandsf; Vetsuisse
Faculty, University of Zürich, Zürich, Switzerlandg
E.K., H.R.J., and D.M. contributed equally to this work. R.D. and V.T. contributed equally to this work.
ABSTRACT The recent emergence of a novel human coronavirus (HCoV-EMC) in theMiddle East raised considerable concerns,
as it is associated with severe acute pneumonia, renal failure, and fatal outcome and thus resembles the clinical presentation of
severe acute respiratory syndrome (SARS) observed in 2002 and 2003. Like SARS-CoV, HCoV-EMC is of zoonotic origin and
closely related to bat coronaviruses. The human airway epithelium (HAE) represents the entry point and primary target tissue
for respiratory viruses and is highly relevant for assessing the zoonotic potential of emerging respiratory viruses, such as HCoV-
EMC. Here, we show that pseudostratified HAE cultures derived from different donors are highly permissive to HCoV-EMC in-
fection, and by using reverse transcription (RT)-PCR and RNAseq data, we experimentally determined the identity of seven
HCoV-EMC subgenomic mRNAs. Although the HAE cells were readily responsive to type I and type III interferon (IFN), we ob-
served neither a pronounced inflammatory cytokine nor any detectable IFN responses following HCoV-EMC, SARS-CoV, or
HCoV-229E infection, suggesting that innate immune evasionmechanisms and putative IFN antagonists of HCoV-EMC are op-
erational in the new host. Importantly, however, we demonstrate that both type I and type III IFN can efficiently reduce HCoV-
EMC replication in HAE cultures, providing a possible treatment option in cases of suspected HCoV-EMC infection.
IMPORTANCE A novel human coronavirus, HCoV-EMC, has recently been described to be associated with severe respiratory tract
infection and fatalities, similar to severe acute respiratory syndrome (SARS) observed during the 2002-2003 epidemic. Closely
related coronaviruses replicate in bats, suggesting that, like SARS-CoV, HCoV-EMC is of zoonotic origin. Since the animal reser-
voir and circumstances of zoonotic transmission are yet elusive, it is critically important to assess potential species barriers of
HCoV-EMC infection. An important first barrier against invading respiratory pathogens is the epithelium, representing the en-
try point and primary target tissue of respiratory viruses. We show that human bronchial epithelia are highly susceptible to
HCoV-EMC infection. Furthermore, HCoV-EMC, like other coronaviruses, evades innate immune recognition, reflected by the
lack of interferon andminimal inflammatory cytokine expression following infection. Importantly, type I and type III interferon
treatment can efficiently reduce HCoV-EMC replication in the human airway epithelium, providing a possible avenue for treat-
ment of emerging virus infections.
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Coronaviruses are enveloped positive-stranded RNA viruses ofveterinary andmedical importance that are associatedmainly
with respiratory and enteric infections (1, 2). Some animal coro-
naviruses have long been known to cause severe diseases. In hu-
mans, however, it was long believed that coronaviruses cause
mainly less severe respiratory infections known as the common
cold. This changed with the appearance of the severe acute respi-
ratory syndrome-associated coronavirus (SARS-CoV) which
caused for the first time a coronavirus-induced life-threatening
disease in humans and was responsible for the 2002-2003 epi-
demic involving more than 8,000 reported cases and almost 800
fatalities (1). The emergence of a novel coronavirus, HCoV-EMC,
raises concerns that we may again face an epidemic caused by a
zoonotic coronavirus (3). HCoV-EMC is associated with severe
respiratory tract infection, renal failure, and fatalities (4, 5) and is,
like SARS-CoV, closely related to bat coronaviruses (3). Since the
HCoV-EMC animal reservoir and circumstances of zoonotic
transmission are yet elusive, it is critically important to assess
which barriers of HCoV-EMC host switching and human-to-
human transmission are operational.
An important first barrier against invading respiratory patho-
gens is the respiratory epithelium, which represents the entry
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FIG 1 Replication of HCoV-EMC and SARS-CoV on HAE cultures. (A) HAE cultures from three donors (0712, black; 1001, light gray; 1505, dark gray) were
prepared as described previously (7) and infected with HCoV-EMC or SARS-CoV (MOI  0.1). Progeny virus release at the apical (top and bottom) and
basolateral (middle) surfaces of HCoV-EMC- or SARS-CoV-infected HAE cultures was determined as genome equivalents (GE) or plaque-forming units (PFU)
per ml at the indicated hpi by using quantitative real-time reverse transcription-PCR (qRT-PCR) specific for HCoV-EMC (16) and SARS-CoV (17) or titration
of infectious particles on Vero cells. Experiments were performed in triplicate for each donor. Data are depicted as mean values standard deviations (SD); nd,
not detected. (B) HCoV-EMC- and SARS-CoV-infected (MOI 0.1) or mock-treated HAE cell cultures were fixed 48 hpi with 6% PFA and immunostained
using the procedure as described (18). Rabbit polyclonal antiserum directed against SARS-CoV Nsp3 (green; anti-SARS-CoV antibody; Rockland) and mouse
monoclonal antibody directed against dsRNA (red; J2; English & Scientific Consulting Bt.) were used as primary antibodies. Dylight 488-labeled anti-mouse IgG
(HL) and Dylight 647-labeled anti-rabbit IgG (HL) (Jackson Immunoresearch) were applied as secondary antibodies, followed by two separate incubation
stepswithCy3-conjugatedmouse anti--tubulin antibody (light blue; Sigma) for staining of ciliated cells andDAPI (4’,6-diamidino-2-phenylindole; Invitrogen)
for staining nuclei (dark blue). Imageswere acquired using anEC, Plan-Neofluor 63/1.40 oil differential inference contrast (DIC)M27 objective on aZeiss LSM
710 confocal microscope. Image capture, analysis, and processing were performed using the ZEN 2010 (Zeiss) and Imaris (Bitplane Scientific Software) software
packages. Representative images are shown from one (1505) of three donors. (C) Schematic representation of sequence reads of an RNAseq analysis of
poly(A)-containing RNA derived fromHCoV-EMC-infected HAE cultures (MOI 1; 6 hpi). Single reads are depicted in green (sense) and red (antisense). The
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point and primary target tissue of respiratory viruses. To assess the
zoonotic potential of HCoV-EMC, it is therefore critically impor-
tant to determine if the human respiratory epithelium is suscep-
tible to HCoV-EMC infection. To address this question, we used
human airway epithelium (HAE) cultures that morphologically
and functionally resemble the upper conducting airways in vivo
(6). The HAE culture system is based on primary human bron-
chial epithelial cells obtained by biopsy, brushing, surgery, or lung
transplant. Isolated bronchial epithelial cells aremanipulatedwith
chemically defined medium to initiate their differentiation into a
pseudostratified human airway epithelial culture. When differen-
tiation is complete, the pseudostratifiedHAE cell layer (i) contains
basal, secretory, columnar, and ciliated cell populations and (ii)
will generate mucus (6, 7). Therefore, this in vitro system recapit-
ulates many aspects of the human airway epithelium, namely, the
presence of well-defined cell types of the human airway epithe-
lium, and physical barriers, such as the mucous layer.
To this end, we have infected fully differentiated HAE cultures
derived from three different donors with HCoV-EMC (3, 5) or
SARS-CoV (strain Frankfurt-1) at a multiplicity of infection
(MOI) of 0.1 and assessed viral growth kinetics. As shown in
Fig. 1A, HAE cells are highly susceptible toHCoV-EMC infection,
with peak virus production already at 48 h postinfection (hpi). In
contrast, replication of SARS-CoV appeared slower and reached
peak virus production later at 72 to 96 hpi (Fig. 1A). For both
viruses, the vast majority of progeny virus was released at the
apical side of HAE cultures, i.e., toward themucous layer (Fig. 1A,
top and bottom), compared to the lower andnot always detectable
virus release at the basolateral side, i.e., toward the medium
(Fig. 1A, middle). We further analyzed HCoV-EMC and SARS-
CoV infection of HAE cultures by immunofluorescence micros-
copy and stained for ciliated cells (-tubulin), double-stranded
(ds) RNA (as a marker for infected cells), and replicase gene-
encoded nonstructural protein 3 (Nsp3; as a marker for corona-
virus replicase-transcriptase complexes). As shown in Fig. 1B,
HCoV-EMC-infected cells were readily identified with a cross-
reacting polyclonal antiserum directed against SARS-CoV Nsp3
or a monoclonal antibody directed against dsRNA, which both
visualized the characteristic punctuated perinuclear staining pat-
tern for coronavirus replicase-transcriptase complexes. HCoV-
EMC infected predominantly nonciliated cells, suggesting that the
putative receptor for HCoV-EMC host cell entry is likely to be
expressed on nonciliated cells of the human bronchial epithelium.
We also analyzed intracellular HCoV-EMC-derived mRNAs by
using an RNAseq approach. Total RNA from HCoV-EMC-
infectedHAE cultures was isolated at 6 hpi usingQiagen’s RNeasy
kit followed by mRNA subtraction according to the manufactur-
er’s protocols. RNA-Seq libraries for an indexed Illumina se-
quencing run were established using ScriptSeqmRNA-Seq library
preparation kit (Epicenter,WI) started from1ngmRNA.Quality-
proven RNA-Seq libraries were analyzed using Illumina’s
HiSeq2500 system according to Illumina’s TruSeq protocols for
single reads (TruSeq SBS kit version 3-HS; 50 cycles). Data anal-
ysis was performed using CLC Genomics workbench 5.5 (CLC
bio, Denmark). Before single-read mapping, raw reads were
trimmed to eliminate ambiguous or remaining adapter sequences.
We used all reads collected from 3 donors in duplicate experi-
ments (total of 6 datasets) that failed tomap to the human genome
(25,053,494 out of 195,541,919 reads) for an alignment against the
publishedHCoV-EMCgenome sequence (GenBank accession no.
JX869059.2). A total of 1,616 out of 25,053,494 (0.006%) reads
could be assigned to the HCoV-EMC genome, and we observed a
genome coverage reflecting the characteristic mRNA replication
and transcription pattern expected for the coronavirus nested set
of viral mRNAs (Fig. 1C). Indeed, we could identify several reads
representing leader-body fusion sequences of predicted HCoV-
EMC mRNAs 2, 4, 7, and 8 (Fig. 1D) (3). In addition, we experi-
mentally determined by reverse transcription (RT)-PCR using to-
tal RNA from HCoV-EMC-infected HAE cells the leader-body
fusion sequences of predicted mRNAs 3, 5, and 6 that were not
represented in the RNAseq data (Fig. 1D; see also Table S1 in the
supplemental material). Collectively, our data show that the hu-
man bronchial epithelium is highly permissive to HCoV-EMC
infection and, accordingly, that all cellular factors required for cell
entry (e.g., receptor), replication, and transcription of viral mR-
NAs, virus assembly, and release are available in the human host.
Next we assessed HAE host cell responses to HCoV-EMC in-
fection on the transcriptional level and compared them to re-
sponses to SARS-CoV and HCoV-229E infection (MOI 1). We
chose to analyze the expression of a set of 15 cellular mRNAs (see
Table S2 in the supplemental material) representing type I IFN,
type III IFN, endosomal and cytoplasmic RNA sensor molecules,
IFN-stimulated genes (ISGs), chemokines, and inflammatory cy-
tokines, at 3, 6, and 12 h following type I IFN (100 IU of IFN-)
and type III IFN (10 ng/ml of IFN-3) (8) treatment or virus
infection. As shown in Fig. 2A, HAE cultures respond swiftly to
type I and type III IFN treatment with upregulation of ISG expres-
sion (i.e., Mx1, 2=-5=-OAS, Stat1, Mda5, Rig-I; Fig. 2A). Notably,
the response of HAE cultures to IFN- treatment supports previ-
ous studies showing high expression of the IFN- receptor
-subunit (IFNLR1) in lungs and in epithelial cells (9). In contrast
to IFN treatment, the HAE cultures displayed only limited early
transcriptional response to coronavirus infection, and particu-
larly, no induction of IFN-was observed inHCoV-EMC-, SARS-
CoV-, and HCoV-229E-infected cells (Fig. 2B). Also the expres-
sion of proinflammatory cytokines was only marginally induced,
mainly in the common cold virus (HCoV-229E)-infected HAE
cultures at 6 hpi. Thus, immediate host responses to HCoV-EMC
infection of HAE cultures are very similar to those observed in
SARS-CoV- and HCoV-229E-infected cells, suggesting that
HCoV-EMC is alreadywell adapted to replication inHAE cultures
and that the human bronchial epithelium is not capable to mount
a strong innate immune response in the absence of professional
cytokine-producing cells, such as plasmacytoid dendritic cells,
conventional dendritic cells, and macrophages (2, 10).
Since HAE cultures responded well to type I and type III IFN
Figure Legend Continued
density of reads exceeding 34 for particular regions are shown condensed in gray. Blue arrows depict HCoV-EMC genes and open reading frames (ORFs). (D)
Summary of detected HCoV-EMC mRNAs. Leader-body junctions of HCoV-EMC mRNAs are shown with 15 nucleotides upstream and downstream of the
transcription regulatory sequence (TRS; bold). Numbers depict corresponding nucleotide positions in theHCoV-EMCgenome. For all 8 viralmRNAs, theORFs
residing in the unique region and the method used for identification (RT-PCR or RNAseq) are indicated.












FIG 2 Human coronavirus-host interaction. (A) Gene expression analysis of IFN-treated HAE cultures. HAE cultures derived from three different donors were used
untreated orwere stimulated from the basolateral sidewith recombinant IFN- (100 IU/ml; IFN-A/Dhuman; Sigma) or recombinant IFN-3 (10 ng/ml) (8) for 3, 6,
and 12 h until total cellular RNAwas extracted using RNeasy (Qiagen). Reverse transcriptionwas performedwithMoloneymurine leukemia virus reverse transcriptase
according to the manufacturer’s protocol (Invitrogen) using 1 g of DNase-treated total RNA. Two microliters of diluted cDNA was amplified according to the
manufacturer’sprotocol,usingprimers targeting15differentmRNAtranscripts (seeTableS1 in the supplementalmaterial).Measurements andanalysiswereperformed
using a LightCycler 480 II instrument and software package (Roche). Cycle profile, 10 min at 95°C; 45 cycles of 10 s at 95°C, 20 s at 55°C, and 20 s at 72°C; followed
by a melting curve step to confirm product specificity. Relative gene expression was calculated using the 2Ct method (19) and is shown as fold induction of
IFN-treated samples compared to that of untreated controls. (B) Gene expression analysis of virus-infected HAE cultures. HAE cell cultures were infected with
HCoV-EMC, SARS-CoV, or HCoV-229E (MOI 1), and total cellular RNA was isolated at 3, 6, and 12 hpi. Relative gene expression analysis was performed as
described above. (C) Analysis of virus replication following IFN pretreatment. HAE cell cultures were left untreated or were treated from the basolateral side for
16 h with recombinant IFN- (100 IU/ml; Sigma) or recombinant IFN-3 (10 ng/ml or 100 ng/ml) (8). The basolateral medium was replaced prior to infection
withHCoV-EMC, SARS-CoV, andHCoV-229E (MOI 0.1). Apical progeny virus release was determined at 48 hpi by qRT-PCR and is given as GE perml. Each
bar represents themean SD from independent experiments performed in duplicate usingHAE cultures derived from three different donors. ns, not significant
(P 0.05); *, P 0.05; **, P 0.01 (paired t test). (D) Immunofluorescence analysis of IFN-treated and virus-infected HAE cultures. HAE cultures were fixed
with 6% PFA and immunostained using the procedure as described (18). Mouse monoclonal antibody directed against dsRNA (J2; English & Scientific
Consulting Bt.) was applied as primary antibody and Dylight 488-labeled anti-mouse IgG (HL) as secondary antibody (green; Jackson ImmunoResearch),
followed by staining of cilia with Cy3-conjugated mouse anti--tubulin antibody (red; Sigma). Images were acquired using an EC, Plan-Neofluor 63/1.40 oil
DICM27 objective on a Zeiss 710 confocal laser scanning microscope. Image capture, analysis, and processing were performed using the ZEN 2010 (Zeiss) and
Imaris (Bitplane Scientific Software) software packages. Representative images are shown from one (0401) of three donors.
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treatment, we addressed if these cytokines can reduce replication
of HCoV-EMC, SARS-CoV, and HCoV-229E. HAE cultures de-
rived from three different donors were left untreated or pretreated
with IFN- (100 IU) or IFN-3 (10 ng/ml and 100 ng/ml) (8) 16 h
prior to infection (MOI 0.1) with HCoV-EMC, SARS-CoV, or
HCoV-229E, and apically released progeny virus genomes were
determined by quantitative RT-PCR (qRT-PCR) at 48 hpi. As
shown in Fig. 2C, pretreatment of HAE cultures with IFN- re-
duced replication of HCoV-EMC and HCoV-229E for all three
different donors and reduced replication of SARS-CoV for two of
three donors. Accordingly, we observed a pronounced reduction
of the number of dsRNA-positive cells in IFN--treated HAE cul-
tures that had been infected with HCoV-EMC, SARS-CoV, or
HCoV-229E (Fig. 2D). Notably, pretreatment of HAE cultures
with IFN-3 also reduced replication ofHCoV-EMC, SARS-CoV,
and HCoV-229E for all three donors at both concentrations used
(10 ng/ml and 100 ng/ml). Like for IFN- treatment, we observed
a pronounced reduction of the number of dsRNA-positive cells in
IFN-3-treated and virus-infected HAE cultures, further corrob-
orating the importance of type III IFN in epithelial antiviral host
defense (9, 11).
In summary, we provide here conclusive evidence that the
novel coronavirus HCoV-EMC can productively infect human
bronchial epithelia cultures, suggesting that all necessary host cell
factors for virus entry, RNA synthesis, and virus assembly and
release are available in the humanhost.HCoV-EMCreplication in
HAE cultures was at least as efficient as replication of SARS-CoV
(this study) andHCoV-229E (12).We conclude that HCoV-EMC
is capable of infecting the primary target tissue, the human respi-
ratory epithelium, which is in accordance to the reported clinical
presentation of severe respiratory symptoms (4, 5). HCoV-EMC
has been suggested to have a zoonotic origin, since closely related
coronaviruses are known to replicate in bats. Considering that
there is not yet any study reporting the successful isolation of a bat
coronavirus, HCoV-EMCdiffers compared to known bat corona-
viruses because it displays broad replication capability in diverse
mammalian cell lines (13). Our data show that the highly patho-
genic viruses HCoV-EMC and SARS-CoV can both replicate in
HAE cultures similar to the common cold viruses HCoV-229E,
HCoV-OC43, HCoV-NL63, and HCoV-HKU1 (12). Also, early
host cell responses are very similar between high- and low-
pathogenic human coronaviruses. Thus, although our data depict
the zoonotic potential of HCoV-EMC by demonstrating efficient
replication in the human respiratory epithelium, decisive factors
that impact HCoV-EMC pathogenicity remain to be determined.
Importantly, we could demonstrate that HCoV-EMC replication
is equally vulnerable to the antiviral effects of type I and type III
IFNs, suggesting a possibility to interfere with HCoV-EMC repli-
cation in the human respiratory tract. IFN- treatment has indeed
been explored as therapeutic strategy during the SARS epidemic
and raised considerable promise (14). The critical importance of
type III IFNs in epithelial host defense (11), recent reports that
treatment of hepatitis C virus-infected patients with pegylated
IFN- achieved rapid virological response, while adverse side ef-
fects were minimal (15), and our data concerning efficient inhibi-
tion of HCoV-EMC replication should encourage the further de-
velopment of IFN- treatment options specifically for respiratory
virus and emerging virus infections.
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